Sofosbuvir/GS-5816: Phase II data

A Phase II trial in 75 patients with HCV genotype 1 infection showed that a fixed-dose oral combination of Sovaldi sofosbuvir and GS-5816 plus GS-9857 for 6 weeks led to an SVR12 rate of 93% in trea...